Provectus Biopharmaceuticals, Inc. (PVCT)

Market Cap	30.74M
Revenue (ttm)	657.70K
Net Income (ttm)	-5.40M
Shares Out	420.28M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,000
Average Volume	166,605
Open	0.0728
Previous Close	0.0732
Day's Range	0.0710 - 0.0728
52-Week Range	0.0445 - 0.1517
Beta	0.74
RSI	43.39
Earnings Date	Aug 12, 2025

About PVCT

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company’s lead molecule is rose bengal sodium, a member of a class of molecules called halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and blood cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infec...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: PVCT

Financial Performance

In 2024, PVCT's revenue was $617,140, an increase of 10.66% compared to the previous year's $557,710. Losses were -$4.76 million, 53.5% more than in 2023.